+44 (0) 20 7549 9987 | USA callers: 00-1-718-682-4567

Contact Us Now

“Global Vaccine Contract Manufacturing market set to grow to $3,831.7m by 2025” says new Visiongain report

08 April 2020
Pharma
vaccine contract manufacturing market

Visiongain has launched a new pharma report Vaccine Contract Manufacturing Market 2020: Prospects for Attenuated Vaccine, Inactivated Vaccine, Fluoroquinolones, Subunit Vaccines, Toxoid Vaccines.

The vaccine manufacturing sector has traditionally been conservative in its approach, relying on traditional methods for vaccine production. The vaccine shortages of recent years that were caused by national pandemics (such as avian flu) highlighted the shortcomings of some of these production methods and more recently COVID-19. The increasing demand for vaccines will make it vital for the vaccine manufacturing industry to develop more-efficient methods for producing vaccines.

The lead analyst of the report commented "Major fluctuations in demand are seen in the case of influenza, as was seen during pandemics over the last decade. Unexpectedly, the Coronavirus or COVID-19 outbreak that started from Wuhan, China, has spread across continents, affecting various industries globally. Supply of key materials has been severely disrupted due to the forced quarantine and lack of labour and raw materials. As the link between regional warehouses is not smooth, the allocation of raw materials between regions cannot be carried out successfully; this shortage of raw material and components affected the medical device supply chain.

Respiratory support devices such as life-support machine, atomizer, oxygen generator and monitor are the primary clinical treatment medical devices. Thus, from diagnosis to cure, the need for instruments for measuring temperature, nucleic acid diagnostic kit, antiviral medical products and life-support machine has kept on increasing."

Leading companies featured in the report include AbbVie, Baxter BioPharma Solutions, Boehringer Ingelheim, Catalent, Charles River Laboratories, IDT Biologika, Lonza, Meridian Life Science and others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Stem Cell Technologies and Applications Market Report 2022-2032

The global stem cell technologies and applications market was valued at US$9,247 million in 2021 and is projected to grow at a CAGR of 8.9% during the forecast period 2022-2032.

01 December 2022

Read

Visiongain Publishes Biosimilars and Follow-On Biologics Market Report 2023-2033

The biosimilars and follow-on biologics market is valued at US$19,668.3 million in 2022 and is projected to grow at a CAGR of 31.14% during the forecast period 2023-2033.

01 December 2022

Read

Visiongain Publishes Medical Imaging Market Report 2022-2032

The Medical Imaging market was valued at US$38.6 billion in 2021 and is projected to grow at a CAGR of 5.46% during the forecast period 2022-2032.

30 November 2022

Read

Visiongain Publishes Antibody Drug Conjugates Market Report 2022-2032

The global antibody drug conjugates market was valued at US$3,668 million in 2021 and is projected to grow at a CAGR of 15.1% during the forecast period 2022-2032.

28 November 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever